{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:48:32Z","timestamp":1762458512444},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,3,29]],"date-time":"2007-03-29T00:00:00Z","timestamp":1175126400000},"content-version":"vor","delay-in-days":209,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Paediatrica"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:sec><jats:label \/><\/jats:sec><jats:sec><jats:title>Abstract<\/jats:title><jats:p>Approximately one third of children with malignancy and central venous lines develop catheter\u2010related thrombosis, with the reported sequelae including death, pulmonary embolism, chylothoraces, superior vena cava syndrome and post\u2010thrombotic syndrome. These complications prompt the design and completion of randomized, controlled trials to determine a safe and efficacious therapy to prevent these thromboses. The authors Ruud et al. have presented a well\u2010designed, randomized, controlled trial which demonstrates the lack of utility of using low\u2010dose warfarin to prevent catheter\u2010related thrombosis in children with central lines and acute lymphoblastic leukaemia. The difficulties with warfarin in children are again demonstrated in this study.<\/jats:p><jats:p> <jats:bold>Conclusion:<\/jats:bold> Further studies are warranted using other thromboprophylactic agents with less or no monitoring and fewer drug interactions, including the newer anticoagulant agents such as direct thrombin inhibitors.<\/jats:p><\/jats:sec>","DOI":"10.1080\/08035250600746328","type":"journal-article","created":{"date-parts":[[2006,8,28]],"date-time":"2006-08-28T18:12:40Z","timestamp":1156788760000},"page":"1049-1052","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Thromboprophylaxis of central venous lines in children with cancer: The first steps taken on the long road ahead"],"prefix":"10.1111","volume":"95","author":[{"given":"Patricia","family":"Massicotte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,29]]},"reference":[{"key":"e_1_2_2_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613054"},{"key":"e_1_2_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70149-0"},{"key":"e_1_2_2_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.5.1251.1251"},{"key":"e_1_2_2_5_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-200006000-00013"},{"key":"e_1_2_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2003.09.008"},{"key":"e_1_2_2_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648912"},{"key":"e_1_2_2_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-3-112-6-423"},{"key":"e_1_2_2_9_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1650254","article-title":"Upper extremity deep venous thrombosis in cancer patients with venous access devices *prophylaxis with a low molecular weight heparin (Fragmin)","volume":"75","author":"Monreal M","year":"1996","journal-title":"Thromb Haemost"},{"key":"e_1_2_2_10_2","first-page":"1474","article-title":"A phase III double\u2010blind, placebo\u2010controlled study evaluating the Efficacy and safety of daily low\u2010molecular\u2010weight heparin (dalteparin sodium, frag\u2010min) in preventing catheter\u2010related complications in cancer patients with central venous catheters","volume":"21","author":"Reichardt PKA","year":"2002","journal-title":"Proc Annu Am Soc Clin Onc"},{"key":"e_1_2_2_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.192"},{"key":"e_1_2_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.084"},{"key":"e_1_2_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01736.x"},{"key":"e_1_2_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01734.x"},{"key":"e_1_2_2_15_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.338S"},{"key":"e_1_2_2_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.5.1651.1651"},{"key":"e_1_2_2_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.1.165.165"},{"key":"e_1_2_2_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.8.1998.1998"},{"key":"e_1_2_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70273-1"},{"key":"e_1_2_2_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.9.3007"},{"key":"e_1_2_2_21_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-03-0215"},{"key":"e_1_2_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(03)00099-9"},{"key":"e_1_2_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(03)00059-8"},{"key":"e_1_2_2_24_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.118192"},{"key":"e_1_2_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(03)00100-2"},{"key":"e_1_2_2_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/08035250600729092"},{"key":"e_1_2_2_27_2","first-page":"1843","article-title":"the WARP collaborative group UK. WARP\u2013a multicentre prospective randomized controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs).","volume":"3","author":"Young AMBG","journal-title":"Proceedings of the 2005 American Society of Clinical Oncology Annual Meeting 2005\u20132005"},{"key":"e_1_2_2_28_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.127276"},{"key":"e_1_2_2_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11042"},{"key":"e_1_2_2_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613930"},{"key":"e_1_2_2_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199512000-00011"},{"key":"e_1_2_2_32_2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood.V93.5.1595","article-title":"Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors","volume":"93","author":"Nowak\u2010Gottl U","year":"1999","journal-title":"Blood"},{"key":"e_1_2_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01374.x"},{"key":"e_1_2_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06209.x"}],"container-title":["Acta Paediatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F08035250600746328","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/08035250600746328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:38:29Z","timestamp":1697395109000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/08035250600746328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1080\/08035250600746328"],"URL":"https:\/\/doi.org\/10.1080\/08035250600746328","archive":["Portico"],"relation":{},"ISSN":["0803-5253","1651-2227"],"issn-type":[{"value":"0803-5253","type":"print"},{"value":"1651-2227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"2007-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}